Entera Bio Ltd.

ENTX

IL0011429839

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 23/05/2024 BST			5-day change	1st Jan Change
2.31 ^USD	-2.94%		-11.15%	+285.00%

05-15	Entera Bio Appoints Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member	CI
05-13	Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets for the Treatment of Hypoparathyroidism at ENDO 2024	CI

Entera Bio Ltd. Provides Earnings Guidance for the Year Ending December 31, 2022

March 08, 2022 at 11:30 am

Entera Bio Ltd. expects an operating loss of between $25 and $30 million for the year ending December 31, 2022.

Latest news about Entera Bio Ltd.

Entera Bio Appoints Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member	05-15	CI
Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets for the Treatment of Hypoparathyroidism at ENDO 2024	05-13	CI
Entera Bio Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Entera Bio Ltd. Announces Publication of Oral PTH(1-34) Peptide Tablets Phase 2 Trial Data in the Journal of Bone and Mineral Research	04-08	CI
Entera Bio Ltd. Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs Is Expected Within 10 Months	03-26	CI
Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	03-20	CI
Entera Bio Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-08	CI
Top Premarket Gainers	01-18	MT
Top Premarket Gainers	01-17	MT
Entera Bio Ltd. announced that it has received $6.610594 million in funding	12-21	CI
Entera Bio Ltd. announced that it expects to receive $6.610594 million in funding	12-19	CI
Entera Bio Ltd. Announces Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform	11-29	CI
Entera Bio Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Entera Bio Ltd. Reports Key Milestone Relating to Oral PTH (1-34) Peptide Phase 3 Program	11-09	CI
Entera Bio Ltd. Reports Rapid Pharmacodynamic (Pd) Response and Consistent Pharmacokinetic (Pk) Data for Its First-In-Class Oral Pth(1-34) Mini Tablets At the Asbmr 2023 Annual Meeting	16/10/23	CI
Entera Bio Ltd. Announces Collaboration with OPKO Biologics, Inc. to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes	12/09/23	CI
Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research Annual Meeting	16/08/23	CI
Entera Bio Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23	CI
Entera Bio Ltd Adds Haya Taitel to its Board of Directors	07/06/23	CI
Entera Bio Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	05/05/23	CI
Entera Bio Ltd.'S Oral Delivery of GLP-2 Pre-Clinical Data to Be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics	03/05/23	CI
Steven R. Goldstein Joins Entera Bio Ltd.'s Clinical and Scientific Advisory Board	26/04/23	CI
Entera Bio Ltd. Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program	03/04/23	CI
Entera Bio Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23	CI
Entera Bio Ltd. Auditor Raises 'Going Concern' Doubt	30/03/23	CI

Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.

Sector

Biotechnology & Medical Research

Calendar

01/06/2024 - Endocrine Society Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.31 USD

Average target price

10 USD

Spread / Average Target

+332.90%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ENTERA BIO LTD.	+285.00%	85.17M
VERTEX PHARMACEUTICALS INCORPORATED	+10.79%	115B
REGENERON PHARMACEUTICALS, INC.	+11.65%	106B
BIONTECH SE	-6.20%	24.69B
ARGENX SE	-2.33%	21.97B
GENMAB A/S	-6.03%	19.27B
BEIGENE, LTD.	-13.41%	17.56B
WUXI APPTEC CO., LTD.	-40.50%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+6.64%	14.03B
SAREPTA THERAPEUTICS, INC.	+31.84%	12.13B

Bio Therapeutic Drugs

Entera Bio Ltd.

Equities

ENTX

IL0011429839

Biotechnology & Medical Research

Entera Bio Ltd. Provides Earnings Guidance for the Year Ending December 31, 2022

Latest news about Entera Bio Ltd.

Chart Entera Bio Ltd.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs